Market Research Logo

Opium (Opioid) Addiction - Pipeline Review, H2 2015

Opium (Opioid) Addiction - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Opium (Opioid) Addiction - Pipeline Review, H2 2015’, provides an overview of the Opium (Opioid) Addiction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Opium (Opioid) Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Opium (Opioid) Addiction pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Opium (Opioid) Addiction Overview
Therapeutics Development
Pipeline Products for Opium (Opioid) Addiction - Overview
Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis
Opium (Opioid) Addiction - Therapeutics under Development by Companies
Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes
Opium (Opioid) Addiction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Opium (Opioid) Addiction - Products under Development by Companies
Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
Alkermes Plc
BioDelivery Sciences International, Inc.
Camurus AB
Celtic Pharmaceutical Holdings L.P.
Foresee Pharmaceuticals, LLC
Heron Therapeutics, Inc.
Indivior Plc
INSYS Therapeutics, Inc.
Omeros Corporation
Pfizer Inc.
Relmada Therapeutics, Inc.
Titan Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc.
Opium (Opioid) Addiction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(samidorphan + buprenorphine hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Buprenorphine Hemiadipate Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride depot - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride long acting - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cannabidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FP-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OMS-405 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-5006739 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
samidorphan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TA-CD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Opium Addiction - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Opium (Opioid) Addiction - Recent Pipeline Updates
Opium (Opioid) Addiction - Dormant Projects
Opium (Opioid) Addiction - Discontinued Products
Opium (Opioid) Addiction - Product Development Milestones
Featured News & Press Releases
Sep 28, 2015: Braeburn Announces FDA’s Acknowledgment of Receipt of Probuphine NDA Resubmission; Agency Action Expected by February 27, 2016
Sep 03, 2015: Titan Pharmaceuticals To Present At Rodman & Renshaw 17th Annual Global Investment Conference
Aug 31, 2015: Titan Pharmaceuticals Announces Resubmission of the New Drug Application for Probuphine for the Maintenance Treatment of Opioid Addiction
Jun 08, 2015: Titan Pharmaceuticals Reports Positive Results From Phase 3 Study of Probuphine for Opioid Addiction
Jun 05, 2015: Titan Pharmaceuticals Schedules Conference Call to Review Results From Phase 3 Study of Probuphine for Opioid Addiction
Apr 15, 2015: Phase 3 Study Completion on Schedule for Late Q2, 2015
Apr 02, 2015: Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market
Mar 24, 2015: Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine
Feb 24, 2015: Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine
Jan 06, 2015: Titan Pharmaceuticals to Present at 8th Annual OneMedForum
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Opium (Opioid) Addiction, H2 2015
Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2015
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H2 2015
Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2015
Opium (Opioid) Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H2 2015
Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015
Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H2 2015
Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2015
Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2015
Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H2 2015
Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H2 2015
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2015
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H2 2015
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Opium (Opioid) Addiction Therapeutics - Recent Pipeline Updates, H2 2015
Opium (Opioid) Addiction - Dormant Projects, H2 2015
Opium (Opioid) Addiction - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Opium (Opioid) Addiction, H2 2015
Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report